Literature DB >> 12386696

Hantavirus pulmonary syndrome in Uberaba, Minas Gerais, Brazil.

Mario León Silva-Vergara1, José Carlos Costa, Cristina Hueb Barata, Vítor Guilherme Maluf Curi, Carlos Giovanni Tiveron, Alan César Teixeira.   

Abstract

This report describes the epidemiological and clinical-evolutive characteristics of eight patients with hantavirus pulmonary syndrome (HPS) in Uberaba, Minas Gerais, Brazil. A positive history of contact with rodents was present in 100% of the cases. The time between the onset of symptoms and hospital care was, on average, 3.6 days. All patients showed clinical and laboratory findings suggestive of HPS. Elevated urea and creatinine levels were observed in 6 (75%) cases, PO2 was < 60 mmHg in 100% of the cases, and a chest X-ray demonstrated a bilateral interstitial-alveolar infiltrate. The diagnosis was confirmed by the detection of IgM antibodies against Sin Nombre virus by ELISA. Three patients died as a direct consequence of HPS.

Entities:  

Mesh:

Year:  2002        PMID: 12386696     DOI: 10.1590/s0074-02762002000600005

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  4 in total

Review 1.  A global perspective on hantavirus ecology, epidemiology, and disease.

Authors:  Colleen B Jonsson; Luiz Tadeu Moraes Figueiredo; Olli Vapalahti
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  High-resolution computed tomography findings in hantavirus pulmonary syndrome.

Authors:  Felipe von Ranke
Journal:  Radiol Bras       Date:  2017 Jul-Aug

3.  Hantavirus pulmonary syndrome in Argentina, 1995-2008.

Authors:  Valeria P Martinez; Carla M Bellomo; Maria Luisa Cacace; Paola Suarez; Liliana Bogni; Paula J Padula
Journal:  Emerg Infect Dis       Date:  2010-12       Impact factor: 6.883

4.  Clinical and anatomopathological aspects of patients with hantavirus cardiopulmonary syndrome in Uberaba, Minas Gerais, Brazil.

Authors:  João Paulo Vieira Dos Santos; Sheila Jorge Adad; Mário-León Silva Vergara; Adilha Misson Rua Micheletti
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-10-10       Impact factor: 1.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.